These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16175313)

  • 21. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery.
    Asada M; Nagata M; Mizuno T; Uchida T; Takahashi H; Makita K; Arai H; Kijima S; Echizen H; Yasuhara M
    Eur J Clin Pharmacol; 2021 May; 77(5):735-745. PubMed ID: 33211137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic model of cefazolin in total hip arthroplasty.
    Lanoiselée J; Chaux R; Hodin S; Bourayou S; Gibert A; Philippot R; Molliex S; Zufferey PJ; Delavenne X; Ollier E
    Sci Rep; 2021 Oct; 11(1):19763. PubMed ID: 34611213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs.
    Marcellin-Little DJ; Papich MG; Richardson DC; DeYoung DJ
    Am J Vet Res; 1996 May; 57(5):720-3. PubMed ID: 8723889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man.
    Tsuji A; Nishide K; Minami H; Nakashima E; Terasaki T; Yamana T
    Drug Metab Dispos; 1985; 13(6):729-39. PubMed ID: 2867880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic cefazolin concentrations in morbidly obese patients undergoing sleeve gastrectomy: do we achieve targets?
    Grégoire M; Dumont R; Ronchi L; Woillard JB; Atthar V; Letessier E; Cinotti R; Roquilly A; Deslandes G; Jolliet P; Asehnoune K; Dailly E
    Int J Antimicrob Agents; 2018 Jul; 52(1):28-34. PubMed ID: 29501602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic prophylaxis with cefazolin and gentamicin in cardiac surgery for children less than ten kilograms.
    Haessler D; Reverdy ME; Neidecker J; Brûlé P; Ninet J; Lehot JJ
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):221-5. PubMed ID: 12698406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?
    Edmiston CE; Krepel C; Kelly H; Larson J; Andris D; Hennen C; Nakeeb A; Wallace JR
    Surgery; 2004 Oct; 136(4):738-47. PubMed ID: 15467657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.
    van Kralingen S; Taks M; Diepstraten J; van de Garde EM; van Dongen EP; Wiezer MJ; van Ramshorst B; Vlaminckx B; Deneer VH; Knibbe CA
    Eur J Clin Pharmacol; 2011 Oct; 67(10):985-92. PubMed ID: 21499760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skeletal muscle and plasma concentrations of cefazolin during cardiac surgery in infants.
    Himebauch AS; Nicolson SC; Sisko M; Moorthy G; Fuller S; Gaynor JW; Zuppa AF; Fox E; Kilbaugh TJ
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):2634-41. PubMed ID: 25131168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery.
    Markantonis SL; Kostopanagiotou G; Panidis D; Smirniotis V; Voros D
    Clin Ther; 2004 Feb; 26(2):271-81. PubMed ID: 15038949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefazolin prophylaxis in minimally invasive gynecologic surgery - are dosage and timing appropriate? Prospective study using resampling simulation.
    Lavie M; Lavie I; Cohen A; Levin I; Many A; Fouks Y
    J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102154. PubMed ID: 33905919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefazolin tissue concentrations with a prophylactic dose administered before sleeve gastrectomy in obese patients: a single centre study in 116 patients.
    Cinotti R; Dumont R; Ronchi L; Roquilly A; Atthar V; Grégoire M; Planche L; Letessier E; Dailly E; Asehnoune K
    Br J Anaesth; 2018 Jun; 120(6):1202-1208. PubMed ID: 29793587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery.
    Asada M; Nagata M; Mizuno T; Uchida T; Kurashima N; Takahashi H; Makita K; Arai H; Echizen H; Yasuhara M
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00440. PubMed ID: 30410768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
    Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
    Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal muscle and plasma concentrations of cefazolin during complex paediatric spinal surgery.
    Himebauch AS; Sankar WN; Flynn JM; Sisko MT; Moorthy GS; Gerber JS; Zuppa AF; Fox E; Dormans JP; Kilbaugh TJ
    Br J Anaesth; 2016 Jul; 117(1):87-94. PubMed ID: 27317707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefazolin dosing for surgical prophylaxis in morbidly obese patients.
    Ho VP; Nicolau DP; Dakin GF; Pomp A; Rich BS; Towe CW; Barie PS
    Surg Infect (Larchmt); 2012 Feb; 13(1):33-7. PubMed ID: 22316145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus.
    Salvador E; Oualha M; Bille E; Beranger A; Moulin F; Benaboud S; Boujaafar S; Gana I; Urien S; Zheng Y; Toubiana J; Briand C; Bustarret O; Geslain G; Renolleau S; Treluyer JM; Hirt D
    Clin Microbiol Infect; 2021 Mar; 27(3):413-419. PubMed ID: 32360445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass.
    Hollis AL; Heil EL; Nicolau DP; Odonkor P; Dowling TC; Thom KA
    Surg Infect (Larchmt); 2015 Dec; 16(6):829-32. PubMed ID: 26291478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily cefazolin and probenecid for skin and soft tissue infections.
    Cox VC; Zed PJ
    Ann Pharmacother; 2004 Mar; 38(3):458-63. PubMed ID: 14970368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expected advantage of administering prophylactic antibiotics using target- concentration controlled infusion: Development of a new pharmacokinetic model of cefazolin.
    Kim KM; Jung J; Lee JM; Yang HS; Bang JY; Lee EK; Choi BM; Noh GJ
    Clin Exp Pharmacol Physiol; 2022 Jul; 49(7):731-739. PubMed ID: 35434816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.